🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Minah Kim

Columbia University Irving Medical Center

ORCID: 0000-0003-0883-5320
Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer”.

Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer

eLife(2025)10.7554/elife.104545
N/A
0.275DataRank · unranked
4 citations

Sungsoo Kim, Kibum Kim, Eugene Son, Minah Kim, Kevin Kalinsky +2 more

CDK4/6 initiates Rb inactivation and CDK2 activity coordinates cell-cycle commitment and G1/S transition

Scientific Reports(2022)10.1038/s41598-022-20769-5
N/A
0DataRank · unranked
99 citations

Alessandra Leong, Minah Kim, Hee Won Yang, Sung Soo Kim

Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer

Cell Reports(2023)10.1016/j.celrep.2023.113198
N/A
0DataRank · unranked
57 citations

Jessica Armand, Anton Safonov, Mimi Zhang, Rajesh K. Soni, Gary K. Schwartz +7 more

Kinetics of RTK activation determine ERK reactivation and resistance to dual BRAF/MEK inhibition in melanoma

Cell Reports(2023)10.1016/j.celrep.2023.112570
N/A
0DataRank · unranked
35 citations

Richard D. Carvajal, Minah Kim, Hee Won Yang, Sung Soo Kim

Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer

eLife(2025)10.7554/elife.104545.1
N/A
0DataRank · unranked
0 citations

Sungsoo Kim, Kibum Kim, Eugene Son, Minah Kim, Hee Won Yang +1 more

Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer

eLife(2025)10.7554/elife.104545.2
N/A
0DataRank · unranked
0 citations

Sungsoo Kim, Kibum Kim, Eugene Son, Minah Kim, Kevin Kalinsky +2 more